Effect of Astragalus membranaceus (Fisch.) Bunge extract containing Astragaloside IV on renal function and proteinuria in patients with diabetic nephropathy
Phase 1
- Conditions
- Diabetic nephropathyAstragalus membranaceus,Astragaloside IV,
- Registration Number
- TCTR20200305003
- Lead Sponsor
- FAME Pharmaceuticals Industry Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1.Diabetic nephropathy patients (new cases) with urinary albumin-to-creatinine ratio ≥30 mg/g and/or sustained reduction in eGFR below 60 ml/min/1.73 m2
2.Aged 18 years and above
Exclusion Criteria
1.Prior history of taking Astragalus membranaceus extract and ACEI/ARB
2.Patients with history of allergy to Astragalus membranaceus
3.Pregnant women and lactating mothers
4.Patients with the history of autoimmune diseases
5.Patients with the history of other causes of nephropathy such as obstructive uropathy, hypertension, SLE, glomerulonephritis and polycystic kidney disease
6.Patients on steroids and/or immunosuppressive agents
7.Patients with acute renal failure and renal transplant recipient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method